Supplementary Online Content

Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. *JAMA Netw Open*. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable: Checkpoint inhibitors approved by the US Food and Drug Administration

Drug	*Approval date*	*Tumor indications initially approved*	*Response rate (%) reported at initial approval*	*Approval type (conditional or full)*
Ipilimumab	*2011*	*melanoma*	*10.9*	*full*
	2018	*MSI-CRC*	*49*	*conditional*
	2018	*RCC*	*41.6*	*full*
Nivolumab	*2014*	*melanoma*	*32*	*conditional (initial)*
	2015	*NSCLC*	*19*	*full*
	2015	*RCC*	*21.5*	*full*
	2016	*Hodgkin's lymphoma*	*65*	*conditional*
	2016	*HNSCC*	*13.3*	*full*
	2017	*urothelial carcinoma*	*19.6*	*conditional*
	2017	*MSI-CRC*	*32*	*conditional*
	2017	*hepatocellular carcinoma*	*14.3*	*conditional*
	2018	*SCLC*	*12*	*conditional*
Pembrolizumab	*2014*	*melanoma*	*24*	*conditional (initial)*
	2015	*NSCLC*	*41 (PD-L1 status >50% only)*	*conditional (initial)*
	2016	*HNSCC*	*16*	*conditional*
	2017	*Hodgkin's lymphoma*	*69*	*conditional*
	2017	*urothelial carcinoma*	*21 (previously treated); 29 (cisplatin ineligible)*	*conditional (initial)*
	2017	*MSI*	*36 (colon); 46 (other)*	*conditional*
	2017	*gastric cancer*	*13.3*	*conditional*
	2018	*primary mediastinal large B-cell lymphoma*	*45*	*conditional*
	2018	*cervical cancer*	*14.3*	*conditional*

Atezolizumab	*2016*	*urothelial carcinoma*	*14.8*	*conditional*
	2017	*NSCLC*	*15*	*full*
Avelumab	*2017*	*Merkel cell carcinoma*	*33*	*conditional*
	2017	*urothelial carcinoma*	*13.3*	*conditional*
Durvalumab	*2017*	*urothelial carcinoma*	*17*	*conditional*
	2018	*NSCLC*	*12*	*full*

MSI=microsatellite instability; CRC=colorectal cancer; RCC=renal cell carcinoma; NSCLC=non-small cell lung cancer; HNSCC=head and neck squamous cell carcinoma; SCLC=small cell lung cancer; ; PD-L1= Programmed death-ligand 1.

eFigure 1: Cumulative percentage of oncology patients who are eligible for and who may benefit from checkpoint inhibitor of immunology drugs, by drug type (2011-2018)



eFigure 2: The ratio of patients in oncology who respond to checkpoint inhibitors and who are eligible for them, during years that checkpoint inhibitor drugs had approvals for oncology indications